Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Ovarian, Fallopian Tube and Peritoneal Cancer 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Interleukin-18 × Clear all
NCT01768338 2023-02-10

Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma

Indiana University

Phase 1 Completed
9 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT02277392 2018-09-27

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Gynecologic

Ovarian, Fallopian Tube and Peritoneal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡